Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data validation
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Ovarian cancer treatment drugs industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Cancer type trends
2.1.4 Treatment type trends
2.1.5 Route of administration trends
2.1.6 End-user trends
Chapter 3 Ovarian Cancer Treatment Drugs Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of ovarian cancer
3.2.1.2 Increasing investments in R&D activities
3.2.1.3 Increasing demand for novel treatment for ovarian cancer
3.2.1.4 Growing awareness and early detection
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with the treatment
3.3 Growth potential analysis
3.3.1 By cancer type
3.3.2 By treatment type
3.3.3 By route of administration
3.3.4 By end-user
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis, 2023
4.3 Competitive analysis of major market players, 2023
4.4 Competitive positioning matrix, 2023
4.5 Strategic dashboard, 2023
Chapter 5 Ovarian Cancer Treatment Drugs Market Estimates and Forecast, By Cancer Type, 2018-2032 (USD Million)
5.1 Key trends, by cancer type
5.2 Epithelial ovarian cancer
5.3 Stromal tumors
5.4 Germ cell tumors
Chapter 6 Ovarian Cancer Treatment Drugs Market Estimates and Forecast, By Treatment Type, 2018-2032 (USD Million)
6.1 Key trends, by treatment type
6.2 Targeted therapy drugs
6.2.1 PARP inhibitors
6.2.2 Angiogenesis inhibitors
6.2.3 Other targeted therapy drugs
6.3 Immunotherapy drugs
6.4 Chemotherapy drugs
6.5 Hormone therapy drugs
6.6 Radiation therapy
Chapter 7 Ovarian Cancer Treatment Drugs Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Oral
7.3 Intravenous
7.4 Intraperitoneal
Chapter 8 Ovarian Cancer Treatment Drugs Market Estimates and Forecast, By End-user, 2018-2032 (USD Million)
8.1 Key trends, by end-user
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Other end-users
Chapter 9 Ovarian Cancer Treatment Drugs Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 F. Hoffmann-La Roche AG
10.2 GlaxoSmithKline Plc.
10.3 Immunogen Inc.
10.4 Astrazeneca
10.5 Merck KGaA
10.6 Oasmia Pharmaceutical AB
10.7 Clovis Oncology, Inc.
10.8 Novartis AG
10.9 Bristol-Myers Squibb Company
10.10 Pfizer Inc.
10.11 Eli Lilly and Company
10.12 Aravive Biologics
10.13 Allarity Therapeutics
